Press Releases

Press Releases

Date Title
03/31/20 Vaxart Provides Update on its Oral COVID-19 Vaccine Program
Five COVID-19 Vaccine Candidates in Preclinical Testing Development Services to Enable Manufacture of cGMP Vaccine at Emergent BioSolutions have Started SOUTH SAN FRANCISCO, Calif. , March 31, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant
03/19/20 Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Company Focuses on COVID-19 Program, the First Oral Coronavirus Vaccine Raised total of $19.8 Million from a Registered Direct Offering and Warrant Exercises during Q1 2020 SOUTH SAN FRANCISCO, Calif. , March 19, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company
03/18/20 VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE
Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine SOUTH SAN FRANCISCO, Calif. , March 18, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines
02/27/20 Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market
SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into definitive agreements with several
01/31/20 Vaxart Announces Initiation of Coronavirus Vaccine Program
Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine SOUTH SAN FRANCISCO, Calif. , Jan. 31, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NasdaqGS:  VXRT), a clinical-stage biotechnology company developing oral recombinant
01/22/20 Results from Influenza Challenge Study Published in Lancet Infectious Diseases
Efficacy of Oral Tablet Vaccine Compares Favorably to Market-Leading Fluzone® SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced